417 related articles for article (PubMed ID: 17188733)
1. B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.
Viner KM; Girgis N; Kwak H; Isaacs SN
Virology; 2007 May; 361(2):356-63. PubMed ID: 17188733
[TBL] [Abstract][Full Text] [Related]
2. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of mice with replication-defective human immunodeficiency virus induces cellular and humoral immunity and protects against vaccinia virus-gag challenge.
Baliga CS; van Maanen M; Chastain M; Sutton RE
Mol Ther; 2006 Sep; 14(3):432-41. PubMed ID: 16713742
[TBL] [Abstract][Full Text] [Related]
4. Improved protection conferred by vaccination with a recombinant vaccinia virus that incorporates a foreign antigen into the extracellular enveloped virion.
Kwak H; Mustafa W; Speirs K; Abdool AJ; Paterson Y; Isaacs SN
Virology; 2004 May; 322(2):337-48. PubMed ID: 15110531
[TBL] [Abstract][Full Text] [Related]
5. Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.
Khattar SK; Manoharan V; Bhattarai B; LaBranche CC; Montefiori DC; Samal SK
mBio; 2015 Jul; 6(4):e01005. PubMed ID: 26199332
[TBL] [Abstract][Full Text] [Related]
6. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of the vaccinia virus LC16m8Δ vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol.
Sato H; Jing C; Isshiki M; Matsuo K; Kidokoro M; Takamura S; Zhang X; Ohashi T; Shida H
Vaccine; 2013 Aug; 31(35):3549-57. PubMed ID: 23731631
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag.
Gupta S; Termini JM; Raffa FN; Williams CA; Kornbluth RS; Stone GW
J Virol; 2014 Feb; 88(3):1492-501. PubMed ID: 24227853
[TBL] [Abstract][Full Text] [Related]
10. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
[TBL] [Abstract][Full Text] [Related]
11. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.
Casimiro DR; Chen L; Fu TM; Evans RK; Caulfield MJ; Davies ME; Tang A; Chen M; Huang L; Harris V; Freed DC; Wilson KA; Dubey S; Zhu DM; Nawrocki D; Mach H; Troutman R; Isopi L; Williams D; Hurni W; Xu Z; Smith JG; Wang S; Liu X; Guan L; Long R; Trigona W; Heidecker GJ; Perry HC; Persaud N; Toner TJ; Su Q; Liang X; Youil R; Chastain M; Bett AJ; Volkin DB; Emini EA; Shiver JW
J Virol; 2003 Jun; 77(11):6305-13. PubMed ID: 12743287
[TBL] [Abstract][Full Text] [Related]
12. Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins.
Haglund K; Leiner I; Kerksiek K; Buonocore L; Pamer E; Rose JK
J Virol; 2002 Aug; 76(15):7506-17. PubMed ID: 12097563
[TBL] [Abstract][Full Text] [Related]
13. DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses.
Liu W; Wong YC; Chen SMY; Tang J; Wang H; Cheung AKL; Chen Z
Vaccine; 2018 Jul; 36(31):4621-4632. PubMed ID: 29961605
[TBL] [Abstract][Full Text] [Related]
14. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
[TBL] [Abstract][Full Text] [Related]
15. Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques.
Thippeshappa R; Tian B; Cleveland B; Guo W; Polacino P; Hu SL
Clin Vaccine Immunol; 2015 Dec; 23(3):204-12. PubMed ID: 26718849
[TBL] [Abstract][Full Text] [Related]
16. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
17. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
18. A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.
Someya K; Xin KQ; Matsuo K; Okuda K; Yamamoto N; Honda M
J Virol; 2004 Sep; 78(18):9842-53. PubMed ID: 15331719
[TBL] [Abstract][Full Text] [Related]
19. A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.
Meador LR; Kessans SA; Kilbourne J; Kibler KV; Pantaleo G; Roderiguez ME; Blattman JN; Jacobs BL; Mor TS
Virology; 2017 Jul; 507():242-256. PubMed ID: 28458036
[TBL] [Abstract][Full Text] [Related]
20. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.
Rose NF; Roberts A; Buonocore L; Rose JK
J Virol; 2000 Dec; 74(23):10903-10. PubMed ID: 11069984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
